

Stockpicker intervjuar Curasights CEO Ulrich Krasilnikoff

Stockpicker fick en kort pratstund med Ulrich Krasilnikoff, CEO på Curasight. Det danska biotechbolaget har just nu en nyttjandeperiod av teckningsoptioner i bolaget som ställdes ut i anslutning till listningen på Spotlight Stock Market. Bolaget har i dagarna kommunicerat att ledningspersoner har tecknat sina andelar till 100%.

Först, berätta lite om dig själv och din bakgrund

– I have a technical and financial background as an engineer and certified public accountant, respectively, as well as supplemented with an MBA in strategy and innovation. This also reflects my business career beginning in PWC as an accountant followed by a career in the industry - including more than 10 years as a partner in 2 Danish private equity funds. I was Executive Vice President of BIOFAC Group, which specializes in manufacturing products for the pharmaceutical, veterinary, and nutraceutical industries before I joined Curasight in January 2016, first as an investor and board member - shortly after as CFO and business developer and subsequently also as CEO. Besides, I'm a member of the Board in few other tech companies.

Kan du beskriva Curasights och Er verksamhet för Stockpickers läsare?

– Curasight is developing a platform for high precision diagnosis of cancer (uTRACE®) and anti-cancer radiotherapy (uTREAT®). By combining anti-cancer radiotherapy uTREAT® (therapy) with uTRACE® (diagnostics), the technology is known as Theranostics, Curasight is developing a new cancer technology that is expected to detect and treat cancer and metastases in a much more gentle and efficient way than today's method of external radiation therapy. uTRACE® will specifically seek and bind cancer cells (uPAR expressing) predicting where the anti-cancer radiation treatment, uTREAT®, will bind and work.

Since the IPO, Curasight has met its objectives and valuable clinical and preclinical results have been obtained. Curasight's uTREAT® technology has prior to the IPO already shown promising results in academic preclinical studies in prostate and colorectal cancer, proving that Curasight's therapeutic technology is working. Recently, results from the investigator-initiated Phase II study with uTRACE® in prostate cancer patients gained attention in the March issue of the Journal of Nuclear Medicine, the highest-rated scientific journal within nuclear medicine globally. Furthermore, the article was also named as the best clinical investigation article. This publication underscores the quality of the demonstrated proof-of-concept for the idea of using uPAR-PET as a non-invasive measure of cancer aggressiveness in prostate cancer. The results also support the idea that imaging may replace some of the invasive biopsies currently being taken, something Curasight will take into consideration when planning for a future Curasight sponsored phase III clinical trial in prostate cancer.

Avslutningsvis, vilka är de främsta skälen till att man skall investera i Curasights?

– Curasight's technology is tested in a broad pipeline with six ongoing phase II clinical trials (investigator-initiated) and two completed phase II studies in prostate and breast cancer. According to our assessment, there is currently no other early-stage biotech Company in the field of PET tracer development that has their technology tested in a broader portfolio of investigator initiated clinical trials, in many different cancer indications. In 2017 a phase I/IIa first-in-humans clinical trial with uTRACE® was completed. In 2018 and 2020 phase IIb clinical trials with uTRACE® in breast and prostate cancer were completed, respectively.

Curasight is developing the therapeutic ligand, uTREAT®, that binds to all cancer cells in the body (expressing uPAR – breaking down the normal tissue around the tumour) and locally irradiate cancer with limited irradiation of healthy tissue. This concept represents a more gentle form of radiotherapy compared to traditional external radiation therapy. Combining anti-cancer radiotherapy uTREAT® (therapy) with uTRACE® (diagnostics), the technology is known as Theranostics, is expected to detect and treat cancer and metastases. The Theranostic principle will select the right therapy to the right person at the right time, creating substantial benefits for both patients and the healthcare system.

Detta är en förkortad version av intervjun.

Fullständig intervju hittas via direktlänken <https://www.stockpicker.se/home/stockpicker-intervjuar-curasights-ceo-ulrich-krasilnikoff> och på <https://www.stockpicker.se/>

DISCLAIMER: Detta material har sammanställts av Stockpicker i informationssyfte och ska inte ses som rådgivning. Innehållet har grundats på information från allmänt tillgängliga källor vilka bedömts som tillförlitliga. Sakinnehållets riktighet och fullständighet liksom lämnade prognoser och rekommendationen kan således inte garanteras. Stockpicker lämnar inte i förväg ut slutsatser och eller omdömen i materialet. Åsikter som lämnats i materialet är analytikerns åsikter vid tillfället för upprättandet av materialet och dessa kan ändras. Det lämnas ingen försäkran om att framtida händelser kommer vara i enlighet med åsikter framförda i materialet. Stockpicker fransäger sig allt ansvar för direkt eller indirekt skada som kan grunda sig på detta material. Placeringar i finansiella instrument är förenade med ekonomisk risk. Att en placering historiskt haft en god värdeutveckling är ingen garanti för framtiden. Stockpicker fransäger sig därmed allt ansvar för eventuell förlust eller skada av vad slag det må vara som grundar sig på användandet av materialet.

Vid frågor, kontakta:

Mats Ahlskog, VD Stockpicker AB
Telefon: 08-52504762

Om Stockpicker AB

[Stockpicker](#) har levererat aktietips, analyser och nyheter sedan 1997. Vi är ett oberoende analyshus och unika på den svenska marknaden. Vi analyserar aktier och fonder som är värda att äga, både på kort och lång sikt.

Bifogade filer

[Stockpicker intervjuar Curasights CEO Ulrich Krasilnikoff](#)